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Abstract
Background: Amodiaquine (AQ) along with sulphadoxine-pyrimethamine (SP) offers effective and cheaper
treatment against chloroquine-resistant falciparum malaria in many parts of sub-Saharan Africa. Considering the
previous history of hepatitis, agranulocytosis and neutrocytopenia associated with AQ monotherapy, it becomes
imperative to study the toxicity of co-administration of AQ and SP. In this study, toxicity and resulting global
differential gene expression was analyzed following exposure to these drugs in experimental Swiss mice.
Methods: The conventional markers of toxicity in serum, oxidative stress parameters in tissue homogenates,
histology of liver and alterations in global transcriptomic expression were evaluated to study the toxic effects of
AQ and SP in isolation and in combination.
Results: The combination therapy of AQ and SP results in more pronounced hepatotoxicity as revealed by
elevated level of serum ALT, AST with respect to their individual drug exposure regimen. Furthermore, alterations
in the activity of major antioxidant enzymes (glutathione peroxidase, superoxide dismutase, catalase, glutathione
reductase), indicating the development of oxidative stress, was more significant in AQ+SP combination therapy.
cDNA microarray results too showed considerably more perturbed gene expression following combination therapy
of AQ and SP as compared to their individual drug treatment. Moreover, a set of genes were identified whose
expression pattern can be further investigated for identifying a good biomarker for potential anti-malarial
hepatotoxicity.
Conclusion: These observations clearly indicate AQ+SP combination therapy is hepatotoxic in experimental Swiss
mice. Microarray results provide a considerable number of potential biomarkers of anti-malarial drug toxicity. These
findings hence will be useful for future drug toxicity studies, albeit implications of this study in clinical conditions
need to be monitored with cautions.
Background
Malaria remains to be the major killer disease in the
developing countries that affects lives of more than 500
million people and kills about two million of them
annually [1]. Most of the drugs that are used to treat
malaria can be broadly grouped into 4-aminoquinolines,
8-aminoquinolines, anti-folates, artemisinin derivatives,
hydroxyl naphthoquinones and certain class of
antibiotics, such as doxycycline and clindamycin. 4-ami-
noquiniline derivatives, such as chloroquine and amo-
diaquine (AQ), have been the first-line drugs against
malaria for past several decades. Development of resis-
tance against these drugs in several parts of world
necessitated the use of other drugs along with it for effi-
cient treatment. Malaria treatment guidelines issued by
WHO also recommends the use of AQ and SP combi-
nations for the treatment of chloroquine-resistant
malaria [2-4]. Many clinical trials and field studies, car-
ried primarily in African countries, showed that AQ in
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cases of malaria [5-7]. Although resistance against sul-
phadoxine-pyrimethamine has also been reported in
parts of East Africa [8-10], it remains a good choice for
rest of the world, including West Africa [11]. Notwith-
standing their utility in controlling malaria, most of
these anti-malarials are also associated with risk of
drug-induced toxicity [12-14]. In spite of wide use of
AQ and SP as anti-malarials, there is dearth of scientific
literature describing their potential toxicity [15].
Liver is a vital organ of body and mainly involved in
drug metabolism and its biotransformation. Its unique
position and crucial link with gastro-intestinal tract ren-
ders it highly vulnerable to drug induced toxicity
[16,17]. Previously, Noel et al. had described toxicity
and gene expression alterations in murine liver following
exposure to the anti-relapse anti-malarial drugs prima-
quine [18] and bulaquine [19]. High throughput gene
expression profiling facilitates prediction of toxicity and
interpretation of mechanism of toxicity based on distinct
gene expression changes. The simplest approach to
identify genes of potential interest through several
related experiments is to search for those that are con-
sistently either up- or down-regulated [18-20]. There-
fore, an attempt was made to delineate the mechanism
of anti-malarial drug toxicity in liver tissue following
exposure to AQ and SP combination in murine models.
Methods
Animal groups, drug administration and tissue collection
10-12 weeks old, male Swiss albino mice (Mus muscu-
lus), weighing 25-30 g (Central Drug Research Institute,
Lucknow, India) were randomly assigned to control and
treatment groups. All animal procedures were per-
formed following IAEC approval (115/07/Toxicol./IAEC
dated 11.9.2007) and in compliance to institutional ani-
mal ethics guidelines. The animals were acclimated to
optimal conditions of temperature (25 ± 2°C) and light/
dark cycle (12 h each) before initiation of drug adminis-
tration. The doses for AQ and SP were calculated from
human therapeutic doses [21] based on equivalent body
surface area index [22]. The duration of dosing in mice
was also similar to the human therapeutic regime. Ani-
mals were divided into four groups each consisting of
six animals and were given following dosages orally.
Group 1: 1% DMSO-treated controls, for three conse-
cutive days
Group 2: AQ, 120 mg/kg for three consecutive days
Group 3: 300 mg/kg sulphadoxine and 15 mg/kg pyri-
methamine on day one
Group 4: 120 mg/kg AQ and SP, 300 mg/kg and 15
mg/kg respectively, on day one followed by 120 mg/kg
AQ, on day two and three
All animals were sacrificed by cervical dislocation on
day four of study and liver was taken out after perfusion
with normal saline and a part of it is kept at -70°C until
further analysis. Prior to sacrifice blood was taken out
from cardiac puncture from each animal and left undis-
turbed for 30 minutes for serum separation. A part of
liver tissue was immediately fixed in 10% formal saline
for histological investigations.
Serum biochemistry and liver histology
Alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST) [markers of hepatotoxicity] levels were esti-
mated in the serum with automated biochemical
analyzer using the kits (Beckmann). Fixed liver tissues
were washed overnight, dehydrated through graded alco-
hols and embedded in paraffin wax. Serial sections of 5
μm thickness were stained with haematoxylin and eosin
(H&E) for histological examination.
Biochemical estimation of antioxidant enzymes in liver
tissue fraction
Markers of oxidative stress {tissue levels of lipid peroxi-
dation; LPO [a measure of malondialdehyde (MDA)
concentration] and reduced glutathione level; GSH} and
enzyme activities of major antioxidant enzymes (glu-
tathione peroxidase, superoxide dismutase, catalase, glu-
tathione reductase) were estimated in liver tissue
homogenates using standard tests [23-27].
RNA isolation, cDNA labeling and hybridization
50 mg frozen liver tissue was crushed in liquid nitrogen
and immediately homogenized (Heidolph, Germany) in
1 ml of TRI reagent (Sigma, St. Louis, MO, USA) to iso-
late total RNA. RNA samples with approximately 2:1
ratio of 28S:18S rRNA and 260/280 values ≥ 1.8 were
used for gene expression analysis. Equal amount of RNA
from individuals of the same group was pooled to elimi-
nate inter-individual variations. 25 μg of pooled RNA
was converted into labeled cDNA using CyScribe First
Strand cDNA-labeling kit (Amersham, Buckinghamshire,
UK) following manufacturer’s protocol. Labeled cDNA
was purified with GFX columns as per manufacturer’s
guidelines and subsequently concentrated by evapora-
tion under vacuum after estimating the percent incor-
poration of the dyes with a spectrophotometer (Thermo,
Waltham, MA, USA). Dye swap technical replicate
experiments were performed with aliquots of same RNA
preparation to address inconsistencies regarding dye
incorporation and other technical means of variance.
The Cy5- and Cy3-labeled cDNA samples were mixed
in CyScribe Hyb buffer (Amersham, Buckinghamshire,
UK) containing 10 μg/ml sheared salmon sperm DNA
and 10 μg/ml yeast tRNA (Ambion, Austin, Texas,
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dized to mouse 22.4k arrays [28] for 18 h at 42°C.
Scanning and microarray data analysis
The arrays were washed and subsequently scanned to
collect raw data with Array Scanner III supported with
Image-Quant version 5 (Molecular Dynamics). Intensity
values were extracted from the scanned images with
ArrayVision version 8 (Imaging research, GE healthcare
Biosciences Corp., Piscataway, NJ, USA). Raw intensity
data was analyzed with Avadis Express version 4.3
(Strand life Sciences, Bangalore, India) and the back-
ground corrected intensities were LOWESS normalized
(Cy5 against Cy3) to obtain log (base 2) ratios. Further-
m o r e ,l o g 2v a l u e so fd u p l i c a t es p o t sw e r ea v e r a g e di n
order to get a single mean value to perform k-means
clustering with MeV version 3.1 [TM4, The Institute of
Genomic Research [29]]. Each expression cluster was
further clustered hierarchically with Euclidean distance
matrix and average linkage to identify gene with similar
expression patterns. Raw and log transformed data (ser-
ies accession no. GSE 17392) has been submitted to
Gene Expression Omnibus database [30] and conforms
to MIAME guidelines developed by microarray gene
expression data (MGED) society.
Real time-PCR
mRNA was reverse transcribed according to the manu-
facturer’s instruction (First Strand cDNA Synthesis Kit
for RT-PCR, Invitrogen, California, USA). PCRs were
performed on a Light Cycler 480 System (Roche Diag-
nostics) in 96-well plates. Each reaction was carried out
in 20 μl reaction volume comprising of SYBR Green
qPCR Master Mix (Invitrogen, California, USA), cDNA
template, 200 nM of forward and reverse primers and
nuclease-free water. Serial dilutions of genomic DNA
(250-0.08 ng) were used to generate a quantitative PCR
standard curve. The LightCycler protocol was: 2 min. of
UDG incubation (Invitrogen, California USA) at 50°C
followed by 10 min. of 95°C hot-start enzyme activation;
40 cycles of 95°C denaturation for 15 s, 60°C annealing
and elongation. Melting curve analysis temperatures
were 95°C for 5 s, 70°C for 60 s, and then heating to 95°
C. Water was used as the template for negative control
amplifications included with each PCR. Data were ana-
lyzed using the Roche LightCycler 480 software and Cp
was calculated by the Second Derivate Maximum
Method [31]. The amount of the target mRNA was
examined and normalized to the GAPDH gene mRNA.
The relative expression ratio of a target gene was calcu-
lated as described by Pfaffl [32], based on real-time PCR
efficiencies. Results reported were obtained from at least
three biological replicates and PCR runs were repeated
at least twice.
Statistical analysis
Data were expressed as the mean ± standard error of
the means (S.E.M.). Group means were compared by
one-way analysis of variance (ANOVA) with Newman-
Keuls post analysis test. The differences in the data
obtained were considered statistically significant when
the P-value was less than 0.05. All statistical analysis
was done through using Prism ver.5 (GraphPad Software
Inc., USA).
Results
Effect of amodiaquine and sulphadoxine-pyrimethamine
treatment on the biomarkers of hepatotoxicity and
oxidative stress
Treatment of AQ at 120 mg/kg does not impart hepato-
toxicity or oxidative stress, as levels of ALT, AST, LPO
and GSH were comparable to that of untreated control.
Although administration of SP does not cause any eleva-
tion in level of ALT or AST, it causes appreciable oxida-
tive stress, as a significant elevation in LPO and a
decrease in GSH were observed in mice dosed with SP.
Interestingly, co-administration of AQ and SP (i.e. AQ
+SP) causes both hepatotoxicity as well as oxidative
stress as evident from marked increase in ALT, AST,
LPO and decrease in GSH (Figure 1a, b, c and 1d).
Effect of amodiaquine and sulphadoxine-pyrimethamine
treatment on antioxidant enzymes in liver tissue fraction
Effects of AQ and SP treatment on enzymatic activities
of SOD, catalase, GR and GPx, which are the major
antioxidant enzymes in liver tissue fraction, were investi-
gated. SOD activity was not altered after AQ and SP
treatment, while catalase and GPx activities were drasti-
cally reduced by the treatment of SP and AQ+SP. How-
ever, AQ administration did cause a moderate,
statistically non-significant, increase in the activity of
SOD and catalase. However, activity of GR was
increased by administration of AQ and AQ+SP combi-
nation (Figure 1e, f, g and 1h).
cDNA Microarray analysis of differential gene expression
in murine liver and kidney exposed to anti-malarials
amodiaquine and sulphadoxine-pyrimethamine
Following AQ administration in murine liver, a total of
133 probes were differentially regulated, of which 60
were up-regulated and 73 down-regulated. Some of
these are listed in Table 1. Major important up-regu-
lated probes following AQ dosing included the TAP
binding gene involved in antigen processing, the neo-
genin gene involved in ATP binding, the dihydropyrimi-
dinase like 5 gene involved in axon guidance, the
ankyrin repeat domain 6 gene involved in DNA binding
and genes for GATA binding protein 2 involved in
DNA binding and transcription. Some of the important
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included the DEAD box polypeptide 6 gene involved in
ATP-dependent helicase activity, the voltage dependent
calcium channel L type alpha 1 C subunit gene involved
in calcium channel activity, the lipoma HMGIC fusion
partner-like 2 gene involved in general metabolism, and
the GCN5 gene involved in N-acetyl transferase activity.
Administration of SP in murine liver leads to differen-
tial regulation of 156 probes of which 90 were up-regu-
lated and 66 down-regulated, some of which are listed
in Table 2. Some of the important up-regulated probes
following SP treatment included the DEAH box poly-
peptide 15 gene involved in ATP-dependent helicase
activity, the transketolase gene involved in calcium ion
ALT
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Figure 1 (a - h) Assessment of markers of hepatotoxicity and oxidative stress following exposure of AQ, SP and AQ+SP.G r o u p1 :
untreated control; Group 2: treated with AQ, 120 mg/kg body wt[AQ]; Group 3: treated with sulphadoxine (300 mg/kg) and pyrimethamine (15
mg/kg) [SP]; Group 4: Co-treatment of AQ and SP[AQ+SP]; [*(P < 0.05), ** (P < 0.01), *** (P < 0.001)].
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Page 4 of 10binding, the procollagen type VI alpha 2 genes mainly
involved in cell adhesion, the procollagen lysine 2-oxo-
glutarate 5-dioxygenase 2 genes involved in endopepti-
dase inhibitor activity and a gene coding for RNA
binding motif protein X. Major down-regulated probes
following SP administration included the CDC42 effec-
tor protein 1 (Rho GTPase binding) involved in signal
transduction, the serine (or cysteine) peptidase inhibitor
clade B member 6a gene involved in endopeptidase
inhibitor activity and the cytochrome c oxidase subunit
VIb polypeptide 2 gene involved in electron transfer.
Co-administration of AQ and SP for three consecutive
days resulted in differential regulation of 231 probes,
including 118 up-regulated and 113 down-regulated
probes (Table 3). Major up-regulated probes following
co-exposure of AQ and SP included genes having a
cysteine and histidine-rich domain (CHORD) containing
zinc-binding protein 1, mainly involved in calcium ion
Table 1 List of important differentially expressed probes after administration of AQ in murine Liver
Spot labels Fold Change Gene Name/Description GO : Biological function
11544 2.27 TAP binding protein antigen processing
20523 2.73 RAB39B, member RAS oncogene family GTP binding
18680 2.49 Neogenin ATP binding
11260 2.18 ATPase, Ca
++ transporting, plasma membrane 1 ATP binding
12910 2.20 Dihydropyrimidinase-like 5 axon guidance
18325 3.18 Calcium channel, voltage-dependent, L type, alpha 1D subunit calcium channel activity
9921 3.51 Ankyrin repeat domain 6 DNA binding
18064 6.11 GATA binding protein 2 DNA binding
20032 2.51 Parathyroid hormone receptor 1 G-protein coupled receptor activity
12886 3.62 Transmembrane protein with EGF-like and two follistatin-like domains 1 growth factor activity
21365 3.33 Solute carrier family 38, member 1 L-glutamine transport
492 6.38 DNA segment, Chr 5, Wayne State University 178, expressed phospholipid biosynthesis
22462 -4.53 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 ATP-dependent helicase activity
10941 -2.32 Calcium channel, voltage-dependent, L type, alpha 1C subunit calcium channel activity
2989 -2.69 Nucleoporin 153 DNA binding
22225 -4.12 Suppressor of variegation 4-20 homolog 1 (Drosophila) histone lysine N-methyltransferase activity
15707 -2.09 Lipoma HMGIC fusion partner-like 2 metabolism
9653 -2.55 GCN5 general control of amino acid synthesis-like 2 (yeast) N-acetyltransferase activity
7818 -2.15 Nuclear receptor subfamily 3, group C, member 2 transcription factor activity
Fold change (FC) >2(Up-regulated) and FC<-2 (Down-regulated) and P < 0.01.
Table 2 List of Important differentially expressed probes after administration of SP in murine Liver
Spot labels Fold Change Gene Name/Description GO : Biological function
5638 2.01 Histone deacetylase 9 Histone deacetylase activity
728 2.04 DEAD (Asp-Glu-Ala-Asp) box polypeptide 42 ATP binding
15419 2.33 DEAH (Asp-Glu-Ala-His) box polypeptide 15 ATP-dependent helicase activity
1745 2.66 Transketolase Calcium ion binding
14698 2.76 Procollagen, type VI, alpha 2 Cell adhesion
17252 2.02 Procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 Endopeptidase inhibitor activity
2107 2.62 Lymphocyte antigen 6 complex, locus G6C Extracellular space
14620 2.11 RNA binding motif protein, X chromosome retrogene RNA binding
21645 2.11 RNA binding motif protein 28 RNA binding
12990 2.11 Eukaryotic translation initiation factor 1 Translation factor activity
21844 -3.44 CDC42 effector protein (Rho GTPase binding) 1 Signal transduction
8922 -2.20 Serine (or cysteine) peptidase inhibitor, clade B, member 6a Endopeptidase inhibitor activity
5874 -7.13 Cytochrome c oxidase subunit VIb polypeptide 2 Unknown
6344 -5.56 Tumor protein D52 ———————————
11499 -2.21 Unknown ———————————
11550 -2.54 RIKEN cDNA 4930471M23 gene ———————————
11891 -2.26 TBC1 domain family, member 19 ———————————
Fold change (FC) >2(Up regulated) and FC<-2 (Down regulated) and P < 0.01.
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nucleoside transporter) member 3 gene involved in ion
transport, the Kelch-like 2 Mayven (Drosophila) gene
involved in actin binding, the integrin beta 8 gene
involved in cell adhesion, the gene for suppression of
tumorigenicity (colon carcinoma) involved in cell migra-
tion and mortality factor 4 like 1 gene involved in cell
proliferation. Some of the major down-regulated probes
following AQ+SP treatment were the lysophospholipase
3 gene involved in acyltransferase activity, the mitogen-
activated protein kinase 14 gene involved in ATP bind-
ing, the transforming growth factor beta receptor I gene
involved in ATP binding, the procollagen type VI alpha3
gene involved in cell adhesion, the gene for microfibril-
lar-associated protein 4 involved mainly in cell adhesion,
the BTB and CNC homology 2 genes involved in DNA
binding and the CXXC finger 1 (PHD domain) gene
also involved in DNA binding.
Real time quantitative PCR analysis showed that most
of genes that are differentially expressed in microarray
Table 3 List of Important differentially expressed probes after administration of AQ+SP in murine Liver
Spot labels Fold
Change
Gene Name/Description GO: Biological Function
3557 2.03 Cysteine and histidine-rich domain (CHORD)-containing, zinc-binding protein 1 Calcium ion binding
1410 3.02 Solute carrier family 28 (sodium-coupled nucleoside transporter), member 3 Integral to plasma membrane
16564 2.50 Kelch-like 2, Mayven (Drosophila) Actin binding
5639 2.51 Integrin beta 8 Cell adhesion
10049 2.49 Suppression of tumorigenicity 14 (colon carcinoma) Cell migration
21956 2.25 Mortality factor 4 like 1 Cell proliferation
14809 2.61 Zinc finger, SWIM domain containing 4 Cellular component
21155 2.42 Metal response element binding transcription factor 1 DNA binding
21758 3.61 Regulatory factor X, 3 (influences HLA class II expression) DNA binding
1649 5.71 Polymerase (RNA) III (DNA directed) polypeptide F DNA binding
20006 3.53 Cytochrome b5 type B Electron transport
12949 2.47 GTP binding protein (gene overexpressed in skeletal muscle) GTP binding
492 2.47 DNA segment, Chr 5, Wayne State University 178, expressed Integral to membrane
11468 3.82 DNA segment, Chr 18, ERATO Doi 653, expressed Integral to membrane
9206 2.18 Dystrobrevin binding protein 1 Muscle development
12725 3.03 Dolichyl-di-phosphooligosaccharide-protein glycotransferase N-linked glycosylation via asparagine
14957 3.64 Adenosine deaminase, RNA-specific, B2 RNA binding
15208 2.70 Solute carrier family 25 (mitochondrial carrier, glutamate), member 22 Transporter activity
22601 3.18 Ubiquitin-conjugating enzyme E2D 2 Ubiquitin-dependent protein catabolism
10183 -2.83 Lysophospholipase 3 Acyltransferase activity
6999 -3.22 Mitogen activated protein kinase 14 ATP binding
22383 -2.63 Transforming growth factor, beta receptor I ATP binding
2877 -2.03 Procollagen, type VI, alpha 3 Cell adhesion
18522 -3.11 Microfibrillar-associated protein 4 Cell adhesion
874 -3.24 BTB and CNC homology 2 DNA binding
11690 -8.17 CXXC finger 1 (PHD domain) DNA binding
13862 -2.05 GLI-Kruppel family member GLI3 DNA binding
19141 -2.44 Protein disulfide isomerase associated 6 DNA binding
17585 -2.07 AT rich interactive domain 5B (Mrf1 like) DNA binding
18686 -3.25 Cytochrome b5 type B Electron transport
16362 -3.08 Proteasome (prosome, macropain) subunit, beta type 2 Endopeptidase activity
20020 -4.67 Phosphatidylinositol 3-kinase, C2 domain containing, alpha polypeptide Glycerophospholipid metabolism
13958 -2.83 RAS related protein 1b GTP binding
11531 -3.27 Zinc metallopeptidase, STE24 homolog (S. cerevisiae) Hydrolase activity
13203 -2.64 SH2-B PH domain containing signaling mediator 1 Intracellular signaling cascade
19040 -2.26 Malate dehydrogenase 2, NAD (mitochondrial) Malate dehydrogenase activity
5575 -2.06 Ring finger protein (C3HC4 type) 19 Protein ubiquitination
6605 -3.30 Cleavage and polyadenylation specific factor 4 RNA binding
Fold change (FC) >2(Up regulated) and FC<-2 (Down regulated) and P < 0.01.
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are up-regulated in microarray are up-regulated in real
time PCR too and vice versa (Table 4).
Discussion
Amodiaquine and sulphadoxine-pyrimethamine offer a
great potential as effective anti-malarial against chloro-
quine-resistant malaria and has been used in many parts
of Africa as first-line anti-malarial treatment. However,
considering the previous history of drug-induced hepati-
tis, oxidative stress associated with these drugs particu-
larly AQ, it becomes imperative to study the toxicity
associated with these drugs and their combination in
liver tissue.
Dosages and duration of AQ and SP treatment in
Swiss mice was according to the human therapeutic
equivalent dose and malaria treatment regimen sug-
gested by WHO guidelines [4]. This observation was
that only co-treatment of AQ and SP (AQ+SP) as
recommended combination therapy regimen produces
toxicity and not their individual exposure. However,
treatment with SP alone does produces appreciable oxi-
dative stress leading to a conclusion that observed hepa-
totoxicity and oxidative stress in AQ+SP group might
be a result of either SP toxicity alone or an additive
effect of both these drugs. Interestingly, none of these
drugs or drug combinations results in alterations in nor-
mal liver histology as no histopathological damage was
observed in any sections of liver tissues (Figure 2).
Previous reports showed that anti-malarials, particu-
larly chloroquine, produce oxidative stress in liver tissue
[14], and it was also interesting to study the alteration
in antioxidant profile of major antioxidant enzyme
present in liver tissue fraction. Results showed that the
activity of SOD was not affected either by the treatment
of AQ or SP or their combination (AQ+SP). However,
the level of GPx was significantly reduced in all three
treatment groups and catalase activity was reduced in
SP and AQ+SP group in murine liver fraction. The
decrease in the activity of GPx observed in this study
Table 4 List of genes with their description and expression results by Q-PCR and microarray following treatment with
AQ and SP in murine liver
Gene
Symbol
Gene Name/Description Q-PCR fold
change
Microarray Result Up regulated(▲)/Down
regulated (▼)
ADRA1B Adrenergic receptor, alpha 1b -6 ▲
CYP1A2 Cytochrome P450, family 1, subfamily a, polypeptide 2 -6 ▼
CYP2E1 Cytochrome P450, family 2, subfamily e, polypeptide 1 -5 ▼
SC4MOL Sterol-C4-methyl oxidase-like -4 ▼
H2DM Histocompatibility 2, class II, 1.2 ▲
RAC RAS-related C3 botulinum -1.8 ▼
MCM4 Minichromosome maintenance deficient 4 homolog 5 ▲
VKORC Vitamin K epoxide reductase complex, -1.5 ▼
SC5D Sterol-C5-desaturase (fungal ERG3, delta-5-desaturase)
homolog
7 ▲
ADH1 Alcohol dehydrogenase 1 (class I) 4.8 ▲
GADD45 Growth arrest and DNA-damage-inducible 45 gamma 3.2 ▲
UGT2B1 UDP glucuronosyltransferase 2 family, polypeptide B1 5 ▲
MCM5 Minichromosome maintenance deficient 5 homolog 2.5 ▲
GCGR Glucagon receptor 8 ▲
Note the direction similarity among Q-PCR and microarray findings for gene expression results.
a 
c  d 
b 
Figure 2 Murine liver cross-sections treated with amodiaquine
and sulphadoxine: (a) untreated control, (b) treated with 120
mg/kg of AQ, (c) treated with 300 mg/kg of sulphadoxine and
15 mg/kg of pyrimethamine (SP), (d) Co-exposure of 120 mg/
kg AQ and 300 mg/kg sulphadoxine along with 15 mg/kg of
pyrimethamine (AQ+SP).
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measure substrate in GPX catalyzed reaction. Interest-
ingly, GR activity was observed to increase in AQ and
AQ+SP. The alterations in activities of antioxidant
enzymes of liver observed in the present study were an
indication of oxidative injury brought by the AQ and SP
dosing.
High throughput expression profiling facilitates the
prediction and mechanism of toxicity based on distinct
gene expression changes. Therefore, the study of differ-
ential gene expression in murine liver at high statistical
stringency (i.e. P < 0.01 and expression fold change >2)
clearly indicated that the molecular mechanism of AQ
and SP induced oxidative stress. Furthermore, validation
of microarray findings using qRT-PCR further substanti-
ates these results, which is the most sensitive and accu-
rate method for validating microarray-based differential
expression of genes [33]. The pattern of differential
expression of genes in combination therapy, i.e. the AQ
+SP treated groups, were on an expected line with bio-
chemical observations, showing more robust expression
pattern than either of the drug given alone. Here the
number of differentially expressed probes was 231, far
more differentially expressed genes than AQ (133) or SP
(156) alone. Of the 231 differentially expressed genes in
murine liver after AQ+SP treatment, the number of up-
regulated (118) and of down-regulated (113) probes was
almost similar (Figure 3).
GenMAPP and MAPPFinder tools [34] were utilized
to enlist the various biological pathways that are per-
turbed following exposure to AQ, SP or their combina-
tion (AQ+SP). The pathways that are most affected are
signaling pathways, carbohydrate metabolism, oxidative
stress and drug metabolism (Figure 4). These observa-
tions suggest that anti-malarial drug exposure imparts
stress in liver tissue causing changes in mRNA
expression level of antioxidant pathway and major drug
metabolism pathway.
One of the many genes that are up-regulated in mur-
ine liver following exposure to AQ, SP and their co-
treatment i.e. AQ+SP includes EPRS (glutamyl-prolyl
tRNA synthetase). EPRS is a multifunctional aminoacyl-
tRNA synthetase that catalyzes the aminoacylation of
glutamic acid and proline tRNA species [35]. Sampath
et al. [36] showed that EPRS has a regulated, noncano-
nical activity that blocks synthesis of ceruloplasmin. Fall
in the level of ceruloplasmin which is the major copper
carrier protein, is an indication of hepatic stress [37], so
the elevation in the level of EPRS following anti-malarial
drug treatment can explain the observed hepatic stress.
Supervilin (SVIL) is another gene that is consistently
up-regulated in murine liver following exposure to AQ,
SP and their combination. This gene codes for a pro-
tein, which is tightly associated with both actin fila-
ments and plasma membranes, suggesting that it forms
a link between the actin cytoskeleton and the mem-
brane. An up-regulated SVIL (which is required for
membrane integrity) following drug treatment may be
an explanation for the rise in lipid peroxidation level
observed in the present study. It appears that mem-
brane damage following anti-malarial drug treatment is
an inducing factor for up regulation of supervillin.
Some of the many genes that were up-regulated in the
present study include HSP90ab1, PAWR, and IKbRb
among others. An up-regulated HSP90ab1 indicates that
anti-malarial drug exposure has resulted in the develop-
ment of hepatic stress. The PAWR genes are found to
be transcriptionally induced by apoptotic signals in the
rat ventral prostate [38]. Woronicz et al. [39] observed
that IKbRb activates NF-kappa-B when overexpressed
and phosphorylate serine residues 32 and 36 of I-kappa-
B-alpha and 19 and 23 of I-kappa-B-beta. Therefore,
upregulated PAWR and IKbRb in murine liver is an
indication of cellular toxicity and inflammatory
responses within liver hepatocytes following anti-malar-
ial exposure.
Figure 3 Total number of differentially expressed genes
following exposure to anti-malarial drugs in murine liver.
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Figure 4 Important biological pathways regulated by
administration of all the three dose categories (AQ, SP and AQ
+SP) in murine liver.
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Page 8 of 10One of the several genes that were down-regulated
following anti-malarial exposure in murine liver is the
myotubularin related protein 2 (MTMR2) gene. The
MTMR2 gene encodes a protein that belongs to the
myotubularin family, which is characterized by the pre-
sence of a phosphatase domain. Berger et al. [40] deter-
mined that mouse MTMR2 gene dephosphorylates
phosphatidylinositol 3-phosphate (PI3P) and phosphati-
dylinositol 3, 5-bisphosphate (PI3, 5P2) with high effi-
ciency and peak activity at neutral pH. A perturbation
in phosphatidylinositol pathway resulting from down
regulated MTMR2 expression is an indication of distur-
bances of signaling pathways following anti-malarial
treatment.
Conclusion
Both biochemical and microarray results suggest that
combination therapy of AQ and SP are more damaging
than their individual monotherapies. Microarray results
further suggests that present anti-malarial combination
therapies lead to inflammatory responses and perturbed
signaling cascade leading to general hepatic stress as
observed in biochemical evaluation of liver tissue.
Furthermore, expression level of EPRS, SVIL, PAWR,
and MTMR2 can be good markers for anti-malarial
drug induced hepatotoxicity. Hence, the present study
can help in understanding anti-malarial drug induced
toxicity. However, the clinical implication of the study
needs to be evaluated further with caution as this study
in experimental mice may not hold equally good in case
of malaria prophylaxis and treatment for human
population.
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